{"id":"osimertinib-tablet","safety":{"commonSideEffects":[{"rate":"55","effect":"Diarrhea"},{"rate":"40","effect":"Rash"},{"rate":"25","effect":"Dry skin"},{"rate":"20","effect":"Nausea"},{"rate":"15","effect":"Fatigue"},{"rate":"10","effect":"Stomatitis"},{"rate":"1-2","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL3545063","moleculeType":"Small molecule","molecularWeight":"595.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Osimertinib selectively targets activating EGFR mutations (exon 19 deletions, L858R) and the T790M resistance mutation that emerges during first- or second-generation EGFR inhibitor therapy. By covalently binding to the ATP-binding pocket of mutant EGFR, it prevents autophosphorylation and downstream proliferation signals (MAPK/PI3K pathways), leading to cell cycle arrest and apoptosis in EGFR-mutant lung cancer cells.","oneSentence":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:55.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line)"},{"name":"Metastatic non-small cell lung cancer with EGFR T790M mutation (second-line, after progression on first/second-generation EGFR inhibitors)"}]},"trialDetails":[{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT05801029","phase":"PHASE2","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-18","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":68},{"nctId":"NCT05388669","phase":"PHASE3","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-05","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":418},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT05647122","phase":"PHASE1","title":"First in Human Study of AZD9592 in Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-21","conditions":"Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms","enrollment":403},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT03133546","phase":"PHASE2","title":"Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-05-31","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":155},{"nctId":"NCT04487080","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-30","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1074},{"nctId":"NCT03040973","phase":"PHASE2","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-23","conditions":"Advanced Solid Tumors Which Are cMET-dependent","enrollment":29},{"nctId":"NCT07361705","phase":"PHASE1","title":"Zorifertinib With Osimertinib for NSCLC With Meningeal Progression","status":"NOT_YET_RECRUITING","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2026-01-31","conditions":"Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment","enrollment":42},{"nctId":"NCT04486833","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2021-09-03","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":158},{"nctId":"NCT02442349","phase":"PHASE2","title":"Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-22","conditions":"Non-Small Cell Lung Cancer","enrollment":171},{"nctId":"NCT04563871","phase":"PHASE2","title":"Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2020-11-17","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":73},{"nctId":"NCT07322783","phase":"PHASE2","title":"Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-01-01","conditions":"EGFR Positive Non-small Cell Lung Cancer, MET Amplification","enrollment":60},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT07256509","phase":"PHASE2","title":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-30","conditions":"Non-Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT02197234","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT06350097","phase":"PHASE3","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Non-small Cell Lung Cancer","enrollment":582},{"nctId":"NCT05954871","phase":"PHASE1","title":"Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2024-01-08","conditions":"Colorectal Cancer, Non-Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT03667820","phase":"PHASE2","title":"Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-09-26","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":41},{"nctId":"NCT04665206","phase":"PHASE1, PHASE2","title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Vivace Therapeutics, Inc","startDate":"2021-03-24","conditions":"Solid Tumor, Adult, Mesothelioma, NSCLC","enrollment":336},{"nctId":"NCT05215951","phase":"PHASE2","title":"Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-19","conditions":"Lung Cancer","enrollment":4},{"nctId":"NCT04001777","phase":"PHASE1","title":"A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-07-04","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT05020769","phase":"PHASE2, PHASE3","title":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-01-06","conditions":"Non-small Cell Lung Cancer","enrollment":14},{"nctId":"NCT05880706","phase":"PHASE2","title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-07-19","conditions":"Non-small Cell Lung Cancer","enrollment":198},{"nctId":"NCT06868485","phase":"PHASE2","title":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Wayshine Biopharm, Inc.","startDate":"2025-08-18","conditions":"Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04721015","phase":"PHASE1","title":"Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-23","conditions":"Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)","enrollment":81},{"nctId":"NCT04591002","phase":"PHASE2","title":"Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2022-07-26","conditions":"Lung Cancer","enrollment":43},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT06498986","phase":"PHASE2","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06895928","phase":"PHASE2","title":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-03-28","conditions":"Advanced Solid Tumors","enrollment":400},{"nctId":"NCT06908772","phase":"PHASE2, PHASE3","title":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","enrollment":390},{"nctId":"NCT04862780","phase":"PHASE1","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2021-06-29","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms","enrollment":177},{"nctId":"NCT02841579","phase":"PHASE2","title":"Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M","status":"COMPLETED","sponsor":"MedSIR","startDate":"2016-09-02","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT05261399","phase":"PHASE3","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-08-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":324},{"nctId":"NCT05948813","phase":"PHASE2","title":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","status":"RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2023-08-17","conditions":"NSCLC, EGFR Activating Mutation, Brain Metastases","enrollment":420},{"nctId":"NCT05228015","phase":"PHASE1","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","status":"TERMINATED","sponsor":"Ikena Oncology","startDate":"2022-01-07","conditions":"Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM)","enrollment":67},{"nctId":"NCT02094261","phase":"PHASE2","title":"Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-20","conditions":"Non Small Cell Lung Cancer","enrollment":210},{"nctId":"NCT02454933","phase":"PHASE3","title":"Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-15","conditions":"Locally Advanced or Metastatic EGFR T790M+ NSCLC","enrollment":29},{"nctId":"NCT06362980","phase":"PHASE1","title":"A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations","status":"RECRUITING","sponsor":"National Cancer Center, China","startDate":"2024-05-22","conditions":"NSCLC","enrollment":20},{"nctId":"NCT06306456","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC","status":"RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2024-03-05","conditions":"Non-Small Cell Lung Cancer With EGFR Mutation","enrollment":94},{"nctId":"NCT04908956","phase":"PHASE2","title":"Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2022-08-04","conditions":"NSCLC Stage IV, EGFR Gene Mutation","enrollment":6},{"nctId":"NCT06093503","phase":"PHASE3","title":"Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2024-05-31","conditions":"Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06436144","phase":"PHASE2","title":"Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-06","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB","enrollment":93},{"nctId":"NCT05493501","phase":"PHASE3","title":"Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"EQRx International, Inc.","startDate":"2022-12-14","conditions":"NSCLC","enrollment":8},{"nctId":"NCT06391944","phase":"PHASE2","title":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2021-11-21","conditions":"Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation","enrollment":161},{"nctId":"NCT06380348","phase":"PHASE3","title":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-04-26","conditions":"Local Advanced or Metastatic NSCLC","enrollment":398},{"nctId":"NCT03318939","phase":"PHASE2","title":"Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2017-10-13","conditions":"NSCLC","enrollment":648},{"nctId":"NCT04816214","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT05382728","phase":"PHASE3","title":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","status":"RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2022-06-08","conditions":"NSCLC, EGFR Activating Mutation","enrollment":680},{"nctId":"NCT03446417","phase":"PHASE1","title":"A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Zeno Pharmaceuticals, Inc.","startDate":"2018-04-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT02163733","phase":"PHASE1","title":"Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-14","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT02923947","phase":"PHASE1","title":"Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-04","conditions":"Solid Tumours","enrollment":16},{"nctId":"NCT06117644","phase":"","title":"The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-11-01","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA","enrollment":30},{"nctId":"NCT05153408","phase":"PHASE1","title":"(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2022-01-13","conditions":"Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms","enrollment":20},{"nctId":"NCT05489731","phase":"PHASE1","title":"VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.","startDate":"2022-09-21","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":72},{"nctId":"NCT04179890","phase":"","title":"The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-17","conditions":"Non-squamous, Non-Small Cell Lung Cancer","enrollment":462},{"nctId":"NCT04974879","phase":"PHASE2","title":"Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qingdao Central Hospital","startDate":"2021-07-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":20},{"nctId":"NCT04438902","phase":"PHASE2","title":"Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-12-12","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT04811001","phase":"PHASE2","title":"Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations","status":"UNKNOWN","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2020-06-12","conditions":"NSCLC","enrollment":170},{"nctId":"NCT04798638","phase":"PHASE1","title":"A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2021-04-30","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT02908750","phase":"PHASE1","title":"Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-02","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT03784599","phase":"PHASE2","title":"T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-12-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":28},{"nctId":"NCT05477615","phase":"PHASE2","title":"Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases","status":"UNKNOWN","sponsor":"Jin Hyoung Kang","startDate":"2022-08","conditions":"Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT05284994","phase":"PHASE1, PHASE2","title":"TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03-11","conditions":"Nonsmall-cell Lung Cancer","enrollment":160},{"nctId":"NCT03255083","phase":"PHASE1","title":"DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2019-04-10","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":13},{"nctId":"NCT05132777","phase":"PHASE2","title":"Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2021-11-20","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations","enrollment":155},{"nctId":"NCT02197247","phase":"PHASE1","title":"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-04","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT03394118","phase":"PHASE2","title":"TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2017-08-11","conditions":"NSCLC","enrollment":63},{"nctId":"NCT04644432","phase":"PHASE2","title":"Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Herlev and Gentofte Hospital","startDate":"2020-03-06","conditions":"Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms","enrollment":30},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT02756039","phase":"","title":"Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-05-25","conditions":"All Patients Treated With the Product","enrollment":3494},{"nctId":"NCT04029350","phase":"PHASE2","title":"Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-07-31","conditions":"Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT02161770","phase":"PHASE1","title":"Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Solid Tumours","enrollment":30},{"nctId":"NCT02771314","phase":"PHASE2","title":"Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC","status":"UNKNOWN","sponsor":"Hellenic Oncology Research Group","startDate":"2016-08-02","conditions":"Non Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT02317016","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03-10","conditions":"Non Small Cell Lung Cancer","enrollment":44},{"nctId":"NCT03460275","phase":"PHASE2","title":"Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-02-26","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT01951599","phase":"PHASE1","title":"To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-10-09","conditions":"Healthy Volunteers","enrollment":35},{"nctId":"NCT03050411","phase":"PHASE1","title":"Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-05","conditions":"Nonsmall Cell Lung Cancer","enrollment":30},{"nctId":"NCT02491944","phase":"PHASE1","title":"A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07","conditions":"Oncology","enrollment":27},{"nctId":"NCT02451852","phase":"","title":"AZD9291 US Expanded Access Program","status":"NO_LONGER_AVAILABLE","sponsor":"AstraZeneca","startDate":"","conditions":"EGFR T790M Mutation Positive NSCLC","enrollment":""},{"nctId":"NCT02224053","phase":"PHASE1","title":"Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Healthy Volunteer","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo Tagrisso","bevacizumab"],"phase":"phase_3","status":"active","brandName":"Osimertinib tablet","genericName":"Osimertinib tablet","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells. Used for Metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line), Metastatic non-small cell lung cancer with EGFR T790M mutation (second-line, after progression on first/second-generation EGFR inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}